CHD1 knockdown also conferred in vitro resistance to enzalutamide in the human prostate cancer cell lines CWR22Pc, LAPC4, and E006AA (but only in the context of PTEN loss) and in a genetically defined mouse organoid model (Pten−/–) cultured in 3D, as well as in vivo resistance in the CWR22Pc xenograft model (Figures S3A–S3G). This evidence concerns the gene CHD1 and prostate carcinoma.